Phaseline

Companies › Innovent Biologics Technology Limited (Shanghai R&D Center)

Innovent Biologics Technology Limited (Shanghai R&D Center): clinical trials, targets and expected readouts

3 active drug programs in 4 registered trials: 2 Phase 2, 1 Phase 1, 1 Phase 3; Metabolic and endocrine, Ophthalmology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Tigulixostat (IBI128)
Xanthine dehydrogenase inhibitor
XDHPhase 3GoutApr 2027
IBI302–Phase 2Neovascular Age-related Macular Degeneration; Diabetic Macular OedemaDec 2026
IBI3032
GLP-1 receptor agonist
–Phase 1Overweight or Obesity–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07170319IBI3032Phase 1Overweight or ObesityMetabolic and endocrineDec 2025
NCT07275840IBI302Phase 2Neovascular Age-related Macular DegenerationOphthalmologyAug 2026
NCT06908876IBI302Phase 2Diabetic Macular OedemaOphthalmologyDec 2026
NCT07414394Tigulixostat (IBI128)Phase 3GoutMetabolic and endocrineApr 2027

Targets

XDH (1)

Companies with the same targets

Arthrosi Therapeutics Shenyang Sunshine Pharmaceutical Shanghai Institute Of Biological Products

Companies built like this

Ascletis Pharma (China) The United Bio-Technology (Hengqin) JCR Pharmaceuticals Beijing QL Biopharmaceutical Gan & Lee Pharmaceuticals.

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.